anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During cataract surgery an artificial intraocular lens is implanted in the eye to replace the lens and to correct the refraction for distance vision. Misalignment of intraocular lenses can cause severe loss of visual quality. Different types of misalignments are known. Tilt, one type of intraocular lens misalignment is thought to play a negative role for the optical performance in eyes with intraocular lens designs, especially, if they have aspheric, toric, or multifocal optics. For example, in the case of aspheric intraocular lenses, it appears that even slight amount of tilt may result not only in the loss of the effect of reducing spherical aberrations but in more severe cases even a worsening of the optical quality compared to spherical intraocular lenses. In the case of toric intraocular lenses, tilt introduces higher order aberrations potentially mimicking astigmatism. In the case of multifocal intraocular lenses, tilt increases higher order aberrations, which leads to decreased visual quality.

Various methods to measure intraocular lens misalignments have been described. Studies assessing the intraocular lens position have used subjective grading methods at the slit lamp examination or a Scheimpflug camera to assess intraocular lens decentration and tilt. The subjective grading at the slitlamp may display considerable variability between examiners. This method is more qualitative than quantitative and does not allow fine resolution when reporting intraocular lens tilt. The fact that the patient has no standardized target to focus on makes the method even less reliable. Scanning methods such as Scheimpflug photos require a very well dilated pupil exceeding 6mm to assess the intraocular lens position. Additionally, it can be difficult to identify the anatomical structures of the eye that need to be used as points of reference. Scheimpflug camera images have been used for assessing intraocular lens tilt previously, but erroneous results, often due to corneal magnification, have diminished their widespread use. Another possibility to assess tilt is the use of Purkinje reflexes. The light reflections of Purkinje images at ocular surfaces to evaluate ocular alignment have recently been utilized. Since light is reflected at all interfaces of media with a difference in refractive index, these reflections, called Purkinje images, can be used to assess tilt and decentration of intraocular lenses. Two different clinically applicable Purkinjemeter system provide the measurement of intraocular decentration and tilt. The main problem with Purkinje meters is accessibility, as there are only a few prototypes available worldwide.

The most recently developed method for tilt quantification is the use of optical coherence tomography. This method has several advantages compared to the previous methods: optical coherence tomography based devices are available in most clinics, the resolution of modern optical coherence tomography devices is high, and the measurements are reproducible.
Disclosed herein is a composition for treating post-surgical pain comprising: an aqueous carrier; and a lipid phase comprising an anesthetic agent, the lipid phase dispersed within the aqueous carrier. In certain aspects, the aqueous carrier is hydrogel comprised of tyramine substituted hyaluronic acid. In certain embodiments, the hydrogel is formed through di-tyramine crosslinking. In certain embodiments, the degree of tyramine substitution of hyaluronic acid hydroxyl groups is about 0.5% to about 3%. In further aspects, the lipid phase is comprised of a plurality of lipid microparticles. According to certain embodiments, a salt form of the anesthetic unbound by the plurality of lipid microparticles is dissolved in the aqueous carrier.
Hypothermia contributes to a significant portion of neonatal deaths. Kangaroo mother care (KMC) is a safe and effective method of warming; however, it is not always feasible, and not possible in settings such as resuscitation or clinical instability. Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer. After laboratory based prototype testing for safety and efficacy, the investigators aim to study the supervised use of the warmer under routine implementation conditions in a resource-limited setting. The primary aim of Phase 1 is to determine if the infant warmer is a safe, effective, usable and functional addition to KMC. This is planned in a convenience sample of patients in two district hospitals, one in a relatively warm environment, and one in a colder setting using quantitative methods and observer audits of usability and functionality. After determination of safety and effectiveness and making any necessary modifications to the warmer, Phase 2 aims to study the warmer in rural health centers and transport, as this is where we ultimately aim to use the electricity free devices due to the limited access to functioning and stable electricity in these settings. The overall goal of the project is dissemination of the study results, and ultimately the infant warmer to the district and national level for key policy makers and stakeholders, as well as globally via publication.
Systemic Sclerosis is a rare disease characterized by microvascular affection and cutaneous fibrosis. The digital ulcers are a severe and very invalidating complication. The vascular dysfunction is a key element in the pathogenesis of this disease, preceding the fibrosis. The physiopathology involves a vascular ischemia and mechanical factors or cutaneous calcinoses, or local trauma. The treatment of the digital ulcerations of the Systemic Sclerosis is at first preventive within the a good cutaneous and ungual hygiene, with recourse, as a preventive measure, to Bosentan, an endothelin antagonist. Iloprost by intravenous route is the recommended curative treatment, but patients present very frequent and dose - limiting side effects (headaches, vasomotor flushing, nausea, vomiting, maxillary pains, myalgia).

The paradox is that the decrease of the capillary density and the lower microvascular reactivity limits the distribution of the drug at its site of action when it is administered by intravenous route. High doses are then necessary to reach a sufficient concentration in the region of the wound, which generates side effects. The local administration of the drug could allow to by-pass this problem.

The investigator uses a technique for the topical administration of a vasodilator close to iloprost, treprostinil. This technique is iontophoresis. In the previous clinical trials INFLUX-IT and TIPPS, the investigator showed that the local cutaneous administration of treprostinil by cathodal iontophoresis at 0.03 milliAmper(mA)/cm2 is well tolerated (no local or systematic side effect in healthy volunteer, Systemic Sclerosis patients and diabetics). Iontophoresis induced a steady increase of the cutaneous blood flow of fingers. The investigator also showed that treprostinil was detectable in the dermis until 8 hours after the iontophoresis, without significant increase in the plasma. Thus, daily repeated iontophoresis on 10 days on ulcerated areas could allow to obtain therapeutic tissular concentrations.
For each treatment arm, pre-procedural MRI and post procedural MRI will be obtained. Pre-procedural biopsies will be obtained, if possible. Pretreatment genetic expression, proteomic, or metabolomic patterns from the tumor samples will be assessed. Imaging characteristics from tumors will be extracted using automated software-the study will apply a computational analysis system with the capability to extract and analyze imaging characteristics and correlate them to genetic expression, proteomic, and metabolomic tumor characteristics. Imaging findings will be correlated to clinical outcomes and genetic, proteomic, and metabolomic findings to determine association. Imaging findings and genomic, proteomic, and metabolomic tumor characteristics will be correlated to clinical outcomes (time to recurrence, overall survival, 3-month, 6-month, and 1-year survival).
When 800 mg VALSTAR was administered intravesically to patients with carcinoma in situ, VALSTAR penetrated into the bladder wall. The mean total anthracycline concentration measured in bladder tissue exceeded the levels causing 90% cytotoxicity to human bladder cells cultured in vitro. During the two-hour dose-retention period, the metabolism of VALSTAR to its major metabolites N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol in bladder tissue was negligible. After retention, the drug was almost completely excreted by voiding the instillate. Mean percent recovery of VALSTAR, N-trifluoroacetyladriamycin, and total anthracyclines in 14 urine samples from six patients was 98.6%, 0.4%, and 99.0% of the total administered drug, respectively. During the two-hour dose-retention period, only nanogram quantities of VALSTAR were absorbed into the plasma. N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol were measured in blood. 

Total systemic exposure to anthracyclines during and after intravesical administration of VALSTAR is dependent upon the condition of the bladder wall. The mean AUC 0-6hours(total anthracyclines exposure) for an intravesical dose of 900 mg of VALSTAR administered 2 weeks after transurethral resection of bladder tumors (n=6) was 78 nmol/L•hr. In patients receiving 800 mg of VALSTAR 5 to 51 minutes after typical (n=8) and extensive (n=5) TURB tumors, the mean AUC 0-6hoursvalues for total anthracyclines were 409 and 788 nmol/L•hr, respectively. The AUC 0-6hourstotal exposure to anthracyclines was 18,382 nmol/L•hr in one patient who experienced a perforated bladder following a transurethral resection that occurred 5 minutes before administration of an intravesical dose of 800 mg of VALSTAR. Administration of a comparable intravenous dose of VALSTAR (600 mg/m 2; n=2) as a 24-hour infusion resulted in an AUC 0-6hoursfor total anthracyclines of 11,975 nmol/L•hr. These results are shown in FIGURE 2. 

FIGURE 2.Comparison of Mean AUC 0-6hours in VALSTAR Clinical Studies (N=number of patients)
Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
Osteoarthritis (OA), a degenerative joint disorder, has an unclear immune infiltration mechanism in subchondral bone (SCB). Thus, this study aims to discern immune infiltration variations in SCB between early- and late-stages of OA and identify pertinent biomarkers. Utilizing the GSE515188 bulk-seq profile from the Gene Expression Omnibus database, we performed single-sample gene-set enrichment analysis alongside weighted gene co-expression network analysis to identify key cells and immune-related genes (IRGs) involved in SCB at both stages. At the meanwhile, differentially expressed genes (DEGs) were identified in the same dataset and intersected with IRGs to find IR-DEGs. Protein-protein interaction network and enrichment analyses and further gene filtering using LASSO regression led to the discovery of potential biomarkers, which were then validated by ROC curve analysis, single-cell RNA sequencing, qRT-PCR, western blot and immunofluorescence. ScRNA-seq analysis using GSE196678, qRT-PCR, western blot and immunofluorescence results confirmed the upregulation of their expression levels in early-stage OA SCB samples. Our comprehensive analysis revealed lymphocytes infiltration as a major feature in early OA SCB. A total of 13 IR-DEGs were identified, showing significant enrichment in T- or B-cell activation pathways. Three of them (CD247, POU2AF1, and TNFRSF13B) were selected via the LASSO regression analysis, and results from the ROC curve analyses indicated the diagnostic efficacy of these 3 genes as biomarkers. These findings may aid in investigating the mechanisms of SCB immune infiltration in OA, stratifying OA progression, and identifying relevant therapeutic targets.
AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 2 million cells/kg at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
BACKGROUND: Chronic hepatitis B virus (HBV) infection remains a serious health issue, and determining the optimal time for antiviral therapy is challenging. We aimed to assess liver histological changes in patients with HBeAg-positive chronic hepatitis B (CHB) and those with HBeAg-negative CHB who had persistently normal alanine aminotransferase and to determine the association between significant liver injury and various clinical parameters.
METHODS: We retrospectively included, in this study, 339 treatment-naïve patients with chronic HBV infections who had persistently normal alanine aminotransferase and underwent liver biopsy from 2013 to 2023. Histologic assessment was based on the Metavir scoring system to evaluate the association between clinical characteristics and the severity of liver inflammation and fibrosis.
RESULTS: Among the included participants, 138 were HBeAg-positive and 201 were HBeAg-negative. Lower hepatitis B surface antigen (HBsAg) (P = 0.003) and higher aspartate aminotransferase (AST) (P = 0.002) levels were associated with significant necroinflammation, whereas increasing age (P = 0.004) and lower HBV DNA (P < 0.001) levels were associated with significant fibrosis in HBeAg-positive patients with normal ALT levels. Higher HBV-DNA (P = 0.001) and AST levels(P < 0.001) were associated with significant necroinflammation, and higher AST(P < 0.001) levels were associated with significant fibrosis in HBeAg-negative patients.
CONCLUSIONS: A substantial proportion of patients with HBV infection who had normal ALT presented significant liver injury. HBsAg and AST were independent predictive factors for evaluating inflammation, while HBV DNA load and age were independent predictive factors for evaluating fibrosis in the HBeAg-positive group. HBV DNA load and AST were independent predictive factors for evaluating inflammation, while AST were independent predictive factors for evaluating fibrosis in the HBeAg-negative group.
Protein degradation products are prepared by contacting an aqueous solution of blood or the haemoglobin fraction thereof with an antienzyme precipitant consisting of an alum solution or an aluminium salt solution to precipitate catalase and enzyme inhibitors present in the blood, separating the precipitated solids from the supernatant solution which contains soluble blood proteins, and subjecting the blood proteins in the solution to the action of a proteolytic enzyme under conditions of pH and temperature favourable to enzymic hydrolysis.  The pH of the solution of blood may be adjusted to between 4 and 6 prior to the precipitation of the catalase and enzyme inhibitors and the pH of the supernatant solution may be adjusted to approximately 7,4 e.g. with sodium bicarbonate.  Specified aluminium salts are aluminium sulphate and sodium and potassium aluminium sulphate. Specified enzymes are trypsin, chymotrypsin, pancreatin, erepsin and pepsin.  A bactericidal agent e.g. chloroform, thymol, acetone, toluene, chlorobutanol and sodium benzoate, may be present in the supernatant solution during the enzymatic hydrolysis.  The solution containing the proteolytic enzyme may be maintained at a temperature of approximately 37 DEG C. until hydrolysis is complete, and the pH of the solution containing the soluble blood protein hydroysate may be adjusted to lesss than 5 to yield amino acids.
PROBLEM TO BE SOLVED: To obtain a bathing agent composition containing a clouding agent comprising an inorganic pigment covered with a water-soluble polymer and a cationic polymer and capable of dispersing the clouding agent in a bath in good dispersion state over a long period. SOLUTION: This bathing agent composition contains 0.5-10wt.% of an inorganic pigment (e.g. titanium dioxide) coated with a water-soluble polymer (e.g. high mol.wt. polyethylene glycol) and 0.1-5wt.% of a cationic polymer. The cationic polymer is preferably a cationized cellulose having a mol.wt. of 100,000-2,000,000 and a nitrogen content of 0.15-0.4wt.%. The water-soluble polymer-coated inorganic agent and the cationic polymer are especially compounded in a weight ratio of 1/4 to 4, in whose ratio range the water-soluble polymer-coated inorganic pigment is especially stably dispersed. Since the composition exhibits good dispersion stability over a long period without relating to the concentration of the added composition in the hot water of the bath, the unpleasant precipitation of the clouding agent on the bottom of the bath can be prevented.
PCT No. PCT/EP95/00032 Sec. 371 Date Oct. 11, 1996 Sec. 102(e) Date Oct. 11, 1996 PCT Filed Jan. 5, 1995 PCT Pub. No. WO95/19162 PCT Pub. Date Jul. 20, 1995An active substance-containing patch for the controlled release of estradiol or its pharmaceutically acceptable derivatives alone or in combination with gestagens from a backing layer, an active substance-containing reservoir connected thereto and produced by using pressure sensitive adhesives and at least one penetration enhancer, and a removable protective layer is characterized by the fact that the penetration enhancer is selected from substances based on carboxylic acids.
This 5-year study aims to refine and pilot a peer-delivered intervention to improve functional and social recovery to decrease suicide risk; the study consists of two phases. Phase 1 employs a user-centered design approach to refine SUicide Prevention by Peers Offering Recovery Tactics (SUPPORT) aided by scientific and consumer advisory board stakeholders as well as training Peer Specialists to fidelity on pilot cases in an open trial. SUPPORT is a flexibly delivered intervention intended to augment safety planning by addressing functional and social goals personalized to each Veteran's recovery following a suicidal crisis while including cognitive learning strategies to enhance recall and salience of intervention material. Following adaptations from Phase 1, Phase 2 includes a pilot randomized controlled trial of SUPPORT compared to an enhanced standard care condition. Veteran participants in both phases will be quantitatively assessed at baseline, mid-treatment, post-treatment, and 3-months post-treatment (and qualitatively interviewed at post-treatment). Peer Specialists delivering the intervention will also be qualitatively interviewed post-treatment. The primary outcomes to be evaluated is improvement in personal recovery and reduction in suicidal ideation severity. Secondary outcomes concern changes in various domains of personal and social functioning.
Dosage should be individualized for maximum beneficial effect. The usual recommended dose in older children and adults ranges from 2 mg to 20 mg intramuscular or intravenous, depending on the indication and its severity. In some conditions, e.g., tetanus, larger doses may be required. (See dosage for specific indications.) In acute conditions the injection may be repeated within one hour although an interval of 3 to 4 hours is usually satisfactory. Lower doses (usually 2 mg to 5 mg) and slow increase in dosage should be used for elderly or debilitated patients and when other sedative drugs are administered (see WARNINGS and ADVERSE REACTIONS).

For dosage in infants above the age of 30 days and children, see the specific indications below. When intravenous use is indicated, facilities for respiratory assistance should be readily available.
A pharmaceutical composition comprising methoxycarbonyl methyl carbonate (also known as dimethyl dicarbonate) and a pharmaceutically acceptable carrier or diluent. The pharmaceutical composition is for use in treatment or prevention of a skin disease or condition, wherein it is applied by topical administration. Preferably the carrier/diluent is an oil or fat, a natural wax, a petroleum wax, a hydrocarbon or an organic solvent. Also claimed is methoxycarbonyl methyl carbonate for use as a medicament, preferably for the treatment or prevention of human or non-human animal infectious disease, more preferably mastitis. Methoxycarbonyl methyl carbonate for use in wound healing, cicatrisation, dermal disease or a dermal condition is also claimed. Also disclosed is a sterilising, cleaning or disinfecting composition comprising methoxycarbonyl methyl carbonate (also known as dimethyl dicarbonate) in a carrier or diluent. A method of sterilising, cleaning or disinfecting a surface is also claimed, comprising applying said composition to said surface. A wound dressing comprising a wound contact layer comprising methoxycarbonyl methyl carbonate is also disclosed. Preferably the methoxycarbonyl methyl carbonate is coated on a surface of the wound contact layer or incorporated within the wound contact layer.
The invention relates to graphene/bioactive xerogel and its preparation method and use. The graphene/bioactive xerogel comprises graphene and bioactive xerogel. The bioactive xerogel comprises 25 to 80mol% of CaO, 0 to 70mol% of SiO2, 0 to 70mol% of B2O3, and 2 to 10mol% of P2O5. The graphene/bioactive xerogel comprises 0.0024 to 0.024wt% of graphene. Through utilization of graphene in the bioactive xerogel, mineralization time is shortened to 0.5 to 5 hours from normal 7 to 30 days. The sol-gel preparation method can thoroughly avoid a high-temperature synthesis process and satisfies requirements of preparation of a biomedical repair or filling material which is prepared by compounding with a drug, cells or a growth factor and has effects of bone tissue growth promoting and treatment.
The invention provides a health-care quilt which comprises at least a packing layer. The packing layer comprises a surface fabric and a filling material, wherein the filling material contains fragrant cattail wools. The quilt of the invention is soft and comfortable, has heat retention property, comfortableness and air permeability and has the functions of health protection and moist and insect resistance. The fragrant cattail wools are added in the filling material so the health-care quilt has smooth surface, is light, soft and comfortable, and has heat retention property, comfortableness and air permeability. The health-care quilt further has moist and insect resistance and the functions of health protection such as moistening lung, dispelling fire, resisting bacterial, diminishing inflammation, improving eyesight, calming the nerves, regulating the flow of vital energy, decreasing fat, tonifying spleen, nourishing the life, and lengthening the life. Other Chinese medicinal crops which are conducive to sleep are added in the quilt of the invention so the health protection function of the quilt is further strengthened, the sleeping quality of the user can be improved and the physical fitness of the user can also be strengthened.
FIELD: medicine, oncology. SUBSTANCE: invention proposes the new human cytokin - oncoinhibin. Protein oncoinhibin is excreted by human erythroblastoid cells, its molecular mass is about 28 kDa. Oncoinhibin shows different activity with respect to tumors. Invention proposes method of human oncoinhibin preparing also. EFFECT: improved method of preparing, enhanced antitumor activity.
Trelagliptin 25 milligrams (mg) tablet, orally, once weekly for up to 12 months. Participants received interventions as part of routine medical care.